Emma Andrus, Associate Editor

Ami Greene, MD, discusses her beginner and intermediate SDPA fall conference sessions on dermoscopy.

Rebecca Vasquez, MD, presented a session on common, overlapping, and complex pigmented dermatoses.

Olushola Akinshemoyin Vaughn, MD, shared clinical pearls from her work in a vulvar dermatology clinic at the 2023 SDPA fall conference.

Once daily application of tapinarof cream 1% rapidly improved itch in adult patients with varying plaque psoriasis diseases severity, according to a poster presented at SDPA’s fall conference.

Lisa Swanson, MD, PhD, delves into clinical pearls from her SDPA fall conference sessions on infantile hemangiomas and challenging cases in pediatric dermatology.

Catch up on coverage from the second day of the 2023 SDPA Fall Dermatology Conference.

A poster presented at SDPA’s fall conference revealed key insights into the importance of close monitoring and preventative measures in patients with cSCC.

Douglas DiRuggiero, DMSc, PA-C, presented a comprehensive session at the SDPA fall conference on treatment selection for patients with psoriasis.

Tazarotene was significantly less irritating to the skin than trifarotene and numerically less irritating than adapalene, according to a poster presented at SDPA Fall 2023.

Joe Cari, MPAS, PA-C, spoke to SDPA Fall Conference attendees about the importance of maximizing the patient journey from arrival to check out and beyond.

More than 80% of patients did not experience an increase in number of draining tunnels associated with HS by week 52.

Robyn Siperstein, MD, FAAD, reviews highlights and takeaways from her SDPA Fall 2023 sessions discussing considerations in cosmetic dermatology, thought-changing research in aesthetics, and more.

Catch up on coverage from the first day of the 2023 SDPA Fall Dermatology Conference.

Orit Markowitz, MD, discusses pearls her SDPA fall conference sessions, "Melanoma Diagnosis, Outcomes and Survival," and "Advanced Conditions."

A post hoc analysis evaluated the safety, efficacy, and tolerability of IDP-126 gel in Black patients with moderate to severe acne, of which there are limited data and literature describing its outcomes in this patient population.

Renata Block, MMS, PA-C, delves into the important and ever-evolving role of physician assistants in dermatology.

The most common conditions or concerns patients reported having that may influence their selection of a JAK inhibitor included an increased risk of MACE and an age above 65 years.

Re-treatment 12 months after initial hyaluronic acid filler treatment resulted in further infraorbital rejuvenation.

Mast spoke with Dermatology Times about her conference workshop, what she's looking forward to ahead of this week's SDPA conference, and the importance of always maintaining a passion for patients.

When sessions, late-breaking research, and more conclude at SDPA Fall 2023, there is no shortage of things to do in Nashville.

Click here to answer today's poll.

The conference aimed at providing dermatology physician assistants with the latest in the field begins tomorrow in Nashville, Tennessee.

BoNT/E represents a novel approach in the world of neurotoxins, characterized by its rapid onset of action.

Helen Torok, MD, shares her atopic dermatitis insights.

Four grants were awarded for communities in communities in Miami-Dade County, Florida; Los Angeles County, California; rural communities in Oregon, and downtown Philadelphia, Pennsylvania.

Renata Block, MMS, PA-C, shares her atopic dermatitis insights.

Keep up with the latest headlines in dermatology from the past week, including the creation of a dermatology outreach organization centered in Detroit, a tropical skin disease endemic in parts of the US, and more.

The US Food and Drug Administration has approved IDP-126 gel for patients with acne.

The CRL states that additional efficacy data is needed in order to support approval.

82.8% of adult patients with iPsO achieved an IGA score of 0 or 1 indicative of complete or almost complete lesion clearance.